A clear comparison
MOTS-c and tesamorelin appear in metabolic discussions for different reasons. MOTS-c relates to mitochondrial signalling; tesamorelin relates to growth hormone release and visceral-fat research.
The differences at a glance
Reference facts and current product information are separate below. On a small screen, swipe within the table; keyboard users can focus it and scroll with the arrow keys.
| Compare | MOTS-c | Tesamorelin | Retatrutide |
|---|---|---|---|
| Reference · material class | Single peptide | GHRH analogue | Single peptide |
| Reference · identity and composition | MOTS-c. Supplied form and exact specification require matching documentation. | Tesamorelin. Supplied form and exact specification require matching documentation. | Retatrutide. Supplied form and exact specification require matching documentation. |
| Reference · research question | Energy & metabolism | Growth hormone & visceral fat | Weight management |
| Reference · evidence and limitations | Foundational findings include cell and mouse experiments. Cellular energy research should not be read as a demonstrated improvement in everyday energy, athletic performance or weight loss in people. | Visceral fat is fat around internal organs. It is different from total body weight and from the fat under the skin. Findings in people with HIV-associated abdominal fat cannot simply be extended to every weight-management question. | Human trial evidence relates to specified investigational formulations and trial populations. This catalogue vial is not the trial formulation, and a larger package size does not mean a better outcome. |
| Reference · source papers | Lee et al. (2015): MOTS-c and metabolic homeostasis | Falutz et al. (2007): tesamorelin in people with HIV and abdominal fat accumulation | Jastreboff et al. (2023): phase 2 retatrutide obesity trial |
| Product · current sizes and prices | 10 mg · $79.99 In stock20 mg · $109.00 In stock | 10 mg · $109.99 In stock20 mg · $179.99 In stock | 5 mg · $69.99 In stock10 mg · $99.99 In stock20 mg · $179.99 In stock |
| Product · current stock | In stock | In stock | In stock |
| Product · supplied specification | Confirm form, identity and specification for the selected size. A field not reported remains unconfirmed. Product specifications | Confirm form, identity and specification for the selected size. A field not reported remains unconfirmed. Product specifications | Confirm form, identity and specification for the selected size. A field not reported remains unconfirmed. Product specifications |
| Product · matching lot records | No matching published record. Check Lab Results | No matching published record. Check Lab Results | No matching published record. Check Lab Results |
| Product · information and availability | View available options | View available options | View available options |
Product figures come from the current WooCommerce listing in the store currency. Package milligrams are nominal material amounts, not doses. No report for another sample or lot is substituted for a matching record.
Different routes through metabolism
Metabolism is the set of processes by which the body handles energy and materials. It is broad enough to include mitochondrial signalling, hormone systems and appetite-related pathways. MOTS-c and tesamorelin fit under that umbrella without acting in the same way. MOTS-c is a mitochondrial-derived peptide; tesamorelin is a growth hormone-releasing hormone analogue.
Cellular energy is not a body-weight result
Foundational MOTS-c research includes insulin-sensitivity and metabolic findings in experimental models. That is one reason it appears in energy and exercise discussions. A cellular or mouse finding should not be rewritten as proof that a person will have more energy, lose weight or improve athletic performance. The measured outcome and the study population are central to the comparison.
What visceral fat means here
Tesamorelin has been studied in people with HIV-associated abdominal fat accumulation. Visceral fat is the fat around internal organs. It is different from subcutaneous fat under the skin and from total weight on a scale. A result for one fat compartment in one clinical population does not settle every question about body composition.
Where retatrutide fits
Retatrutide is a separate metabolic comparison because it targets GIP, GLP-1 and glucagon receptors. If you arrived through a weight-loss search, read the three-way receptor comparison as well. The current table keeps catalogue sizes and prices visible, but package milligrams cannot rank different molecules by expected effect. Follow the product overviews and original sources for the fuller context.
Common questions
Is MOTS-c a GLP-1 peptide?
Its mitochondrial research background is different from the GLP-1 receptor-agonist pathway.
Are tesamorelin and retatrutide interchangeable?
No. They are different compounds with different mechanisms and study contexts.
Original sources
These papers support the specific mechanisms or study models discussed above. They do not test the current Peptide Place catalogue batches.
- Lee et al. (2015): MOTS-c and metabolic homeostasis ↗
- Falutz et al. (2007): tesamorelin in people with HIV and abdominal fat accumulation ↗
- Jastreboff et al. (2023): phase 2 retatrutide obesity trial ↗
Continue exploring
MOTS-c: current options and full overview →
Tesamorelin: current options and full overview →

